ストックスクリーナーアプリを入手
3.25
0.61%
-0.02
前日終値:
$3.27
開ける：
$3.3
24時間の取引高:
48,714
Relative Volume:
0.03
時価総額：
$6.96M
収益：
$743.00K
当期純損益:
$-7.63M
株価収益率:
-0.261
EPS:
-12.4498
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-16.88%
1か月 パフォーマンス:
+15.25%
6か月 パフォーマンス:
-21.50%
1年 パフォーマンス:
-84.30%
1日の値動き範囲:
$3.20
$3.38
1週間の範囲:
$3.20
$4.13
52週間の値動き範囲:
$2.56
$21.00
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
名前
Can-Fite Biopharma Ltd ADR
セクター
電話
972 3 924 1114
住所
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
3.25 | 6.96M | 743.00K | -7.63M | 0 | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-10-19 | 再開されました | ROTH Capital | Buy |
| 2016-08-29 | 再開されました | Rodman & Renshaw | Buy |
| 2015-11-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-03-30 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Can-Fite Biopharma Ltd ADR (CANF) 最新ニュース
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 - Sahm
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology - Sahm
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
CANF Stock Price, Quote & Chart - ChartMill
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Technical Analysis | Trend, Signals & Chart Patterns | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
CANFCan-Fite Biopharma Ltd ADR Stock Price and Quote - Finviz
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
Can Fite Biopharma stock rises on osteoarthritis study publication By Investing.com - Investing.com South Africa
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com Nigeria
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Can-Fite BioPharma schedules special shareholder meeting as NYSE American issues non-compliance notice - Investing.com
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Sahm
Curious about the most active stocks on Friday? - ChartMill
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Sahm
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Top movers in Monday's session - ChartMill
Jason Kolbert Analyst Performance at D. Boral Capital - MarketBeat
Stock Ratings | Morgan Stanley maintained its "neutral" rating on Palantir Technologies (PLTR) and raised its price target from $155 to $205. - Sahm
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Unusual volume stocks in Friday's session - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Can-Fite Biopharma Ltd ADR (CANF) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):